Skip to main content
Top
Published in: Hepatology International 1/2015

01-01-2015 | Review Article

Immunologic, hemodynamic, and adrenal incompetence in cirrhosis: impact on renal dysfunction

Authors: Louise Madeleine Risør, Flemming Bendtsen, Søren Møller

Published in: Hepatology International | Issue 1/2015

Login to get access

Abstract

Acute kidney injury (AKI) is one of the most severe complications of cirrhosis and is associated with significant morbidity and mortality. Liver fibrosis and liver insufficiency, portal hypertension, systemic vasodilation, and a subsequent hyperdynamic circulation undermine the renal and cardiac function, making cirrhotic patients more susceptible to hemodynamic incidents. In addition, the immune system is impaired in cirrhosis, leading to an exaggerated production of vasoactive mediators, and the adrenal cortisol response is insufficient, which causes further impairment of the vascular tonus, cardiac output, and renal perfusion. Consequently, the cardiovascular and renal dysfunction is aggravated, resulting in a hepatorenal syndrome (HRS). HRS is seen exclusively in patients with liver disease and has been considered an entirely functional prerenal dysfunction, rather than a structural dysfunction, but is not responsive to volume expansion. Recent research indicates that development of hepatic nephropathy represents a continuous spectrum of functional and structural dysfunction and may be precipitated by the inherent immunologic, adrenal, and hemodynamic incompetence in cirrhosis. New research explores several new markers of renal dysfunction that may replace serum creatinine in the future and give new insight on the hepatic nephropathy. Our understanding of the pathophysiological mechanisms causing the immunologic, adrenal, and hemodynamic incompetence, and the impact on renal dysfunction, has improved in recent years, and in this review we aim to highlight recent achievements in this field.
Literature
1.
2.
go back to reference Belcher JM, Garcia-Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology. 2013;57(2):753–762PubMedCentralPubMedCrossRef Belcher JM, Garcia-Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology. 2013;57(2):753–762PubMedCentralPubMedCrossRef
3.
go back to reference Angeli P, Sanyal A, Moller S, Alessandria C, Gadano A, Kim R, et al. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int. 2013;33(1):16–23PubMedCrossRef Angeli P, Sanyal A, Moller S, Alessandria C, Gadano A, Kim R, et al. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int. 2013;33(1):16–23PubMedCrossRef
4.
go back to reference Cardenas A, Gines P. Acute-on-chronic liver failure: the kidneys. Curr Opin Crit Care. 2011;17(2):184–189PubMedCrossRef Cardenas A, Gines P. Acute-on-chronic liver failure: the kidneys. Curr Opin Crit Care. 2011;17(2):184–189PubMedCrossRef
5.
go back to reference Belcher JM, Parikh CR, Garcia-Tsao G. Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol. 2013;11(12):1550–1558PubMedCrossRef Belcher JM, Parikh CR, Garcia-Tsao G. Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol. 2013;11(12):1550–1558PubMedCrossRef
6.
go back to reference Krag A, Bendtsen F, Burroughs AK, Moller S. The cardiorenal link in advanced cirrhosis. Med Hypotheses. 2012;79(1):53–55PubMedCrossRef Krag A, Bendtsen F, Burroughs AK, Moller S. The cardiorenal link in advanced cirrhosis. Med Hypotheses. 2012;79(1):53–55PubMedCrossRef
7.
go back to reference Kakazu E, Kondo Y, Shimosegawa T. The relationship between renal dysfunction and abnormalities of the immune system in patients with decompensated cirrhosis. ISRN Gastroenterol. 2012;2012:123826PubMedCentralPubMedCrossRef Kakazu E, Kondo Y, Shimosegawa T. The relationship between renal dysfunction and abnormalities of the immune system in patients with decompensated cirrhosis. ISRN Gastroenterol. 2012;2012:123826PubMedCentralPubMedCrossRef
8.
go back to reference Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28(1):26–42PubMedCrossRef Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28(1):26–42PubMedCrossRef
10.
go back to reference Liu H, Schuelert N, McDougall JJ, Lee SS. Central neural activation of hyperdynamic circulation in portal hypertensive rats depends on vagal afferent nerves. Gut. 2008;57(7):966–973PubMedCrossRef Liu H, Schuelert N, McDougall JJ, Lee SS. Central neural activation of hyperdynamic circulation in portal hypertensive rats depends on vagal afferent nerves. Gut. 2008;57(7):966–973PubMedCrossRef
11.
go back to reference Wiese S, Hove JD, Bendtsen F, Moller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol. 2014;11(3):177–186 Wiese S, Hove JD, Bendtsen F, Moller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol. 2014;11(3):177–186
12.
go back to reference Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43(2 Suppl 1):S121–S131PubMedCrossRef Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43(2 Suppl 1):S121–S131PubMedCrossRef
13.
go back to reference Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol. 2003;38(Suppl 1):S69–S89PubMedCrossRef Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol. 2003;38(Suppl 1):S69–S89PubMedCrossRef
14.
go back to reference Laffi G, La VG, Pinzani M, Marra F, Gentilini P. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol. 1997;17(6):530–548PubMed Laffi G, La VG, Pinzani M, Marra F, Gentilini P. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol. 1997;17(6):530–548PubMed
15.
go back to reference Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8(5):1151–1157PubMedCrossRef Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8(5):1151–1157PubMedCrossRef
16.
go back to reference Moller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J. 2013;34(36):2804–2811PubMedCrossRef Moller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J. 2013;34(36):2804–2811PubMedCrossRef
17.
go back to reference Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23(1):164–176PubMedCrossRef Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23(1):164–176PubMedCrossRef
18.
go back to reference Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310–1318PubMedCentralPubMed Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310–1318PubMedCentralPubMed
19.
go back to reference Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31PubMedCentralPubMedCrossRef Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31PubMedCentralPubMedCrossRef
20.
go back to reference Caregaro L, Menon F, Angeli P, Amodio P, Merkel C, Bortoluzzi A, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med. 1994;154(2):201–205PubMedCrossRef Caregaro L, Menon F, Angeli P, Amodio P, Merkel C, Bortoluzzi A, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med. 1994;154(2):201–205PubMedCrossRef
21.
go back to reference Figueiredo A, Romero-Bermejo F, Perdigoto R, Marcelino P. The end-organ impairment in liver cirrhosis: appointments for critical care. Crit Care Res Pract. 2012;2012:539412PubMedCentralPubMed Figueiredo A, Romero-Bermejo F, Perdigoto R, Marcelino P. The end-organ impairment in liver cirrhosis: appointments for critical care. Crit Care Res Pract. 2012;2012:539412PubMedCentralPubMed
22.
go back to reference Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008;48(6):2064–2077PubMedCrossRef Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008;48(6):2064–2077PubMedCrossRef
23.
go back to reference Wadei HM, Geiger XJ, Cortese C, Mai ML, Kramer DJ, Rosser BG, et al. Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy. Am J Transplant. 2008;8(12):2618–2626PubMedCrossRef Wadei HM, Geiger XJ, Cortese C, Mai ML, Kramer DJ, Rosser BG, et al. Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy. Am J Transplant. 2008;8(12):2618–2626PubMedCrossRef
24.
go back to reference Trawale JM, Paradis V, Rautou PE, Francoz C, Escolano S, Sallee M, et al. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int. 2010;30(5):725–732PubMedCrossRef Trawale JM, Paradis V, Rautou PE, Francoz C, Escolano S, Sallee M, et al. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int. 2010;30(5):725–732PubMedCrossRef
25.
go back to reference Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology. 2003;37(2):233–243PubMedCrossRef Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology. 2003;37(2):233–243PubMedCrossRef
26.
go back to reference Belcher JM, Edelstein CL, Parikh CR. Clinical applications of biomarkers for acute kidney injury. Am J Kidney Dis. 2011;57(6):930–940PubMedCrossRef Belcher JM, Edelstein CL, Parikh CR. Clinical applications of biomarkers for acute kidney injury. Am J Kidney Dis. 2011;57(6):930–940PubMedCrossRef
27.
go back to reference Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function—a review. Clin Chem Lab Med. 1999;37(4):389–395PubMedCrossRef Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function—a review. Clin Chem Lab Med. 1999;37(4):389–395PubMedCrossRef
28.
go back to reference Sharawey MA, Shawky EM, Ali LH, Mohammed AA, Hassan HA, Fouad YM. Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis. Hepatol Int. 2011;5(4):927–933 Sharawey MA, Shawky EM, Ali LH, Mohammed AA, Hassan HA, Fouad YM. Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis. Hepatol Int. 2011;5(4):927–933
29.
go back to reference Seo YS, Jung ES, An H, Kim JH, Jung YK, Kim JH, et al. Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels. Liver Int. 2009;29(10):1521–1527PubMedCrossRef Seo YS, Jung ES, An H, Kim JH, Jung YK, Kim JH, et al. Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels. Liver Int. 2009;29(10):1521–1527PubMedCrossRef
30.
go back to reference Gerbes AL, Gulberg V, Bilzer M, Vogeser M. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut. 2002;50(1):106–110PubMedCentralPubMedCrossRef Gerbes AL, Gulberg V, Bilzer M, Vogeser M. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut. 2002;50(1):106–110PubMedCentralPubMedCrossRef
31.
go back to reference Wan ZH, Wang JJ, You SL, Liu HL, Zhu B, Zang H, et al. Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure. World J Gastroenterol. 2013;19(48):9432–9438PubMedCentralPubMedCrossRef Wan ZH, Wang JJ, You SL, Liu HL, Zhu B, Zang H, et al. Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure. World J Gastroenterol. 2013;19(48):9432–9438PubMedCentralPubMedCrossRef
32.
go back to reference Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40(2):221–226PubMedCrossRef Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40(2):221–226PubMedCrossRef
33.
go back to reference Barakat M, Khalil M. Serum cystatin C in advanced liver cirrhosis and different stages of the hepatorenal syndrome. Arab J Gastroenterol. 2011;12(3):131–135PubMedCrossRef Barakat M, Khalil M. Serum cystatin C in advanced liver cirrhosis and different stages of the hepatorenal syndrome. Arab J Gastroenterol. 2011;12(3):131–135PubMedCrossRef
34.
go back to reference Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis. 2004;43(3):405–414PubMedCrossRef Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis. 2004;43(3):405–414PubMedCrossRef
35.
go back to reference Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen-Philbrook H, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014;60(2):622–632 Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen-Philbrook H, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014;60(2):622–632
36.
go back to reference Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62(1):237–244PubMedCrossRef Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62(1):237–244PubMedCrossRef
37.
go back to reference Nickolas TL, O’Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med. 2008;148(11):810–819PubMedCentralPubMedCrossRef Nickolas TL, O’Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med. 2008;148(11):810–819PubMedCentralPubMedCrossRef
38.
go back to reference Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci. 2012; 57(9):2362–2370 Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci. 2012; 57(9):2362–2370
39.
go back to reference Gerbes AL, Benesic A, Vogeser M, Krag A, Bendtsen F, Moller S. Serum neutrophil gelatinase-associated lipocalin—a sensitive novel marker of renal impairment in liver cirrhosis? Digestion. 2011;84(1):82–83PubMedCrossRef Gerbes AL, Benesic A, Vogeser M, Krag A, Bendtsen F, Moller S. Serum neutrophil gelatinase-associated lipocalin—a sensitive novel marker of renal impairment in liver cirrhosis? Digestion. 2011;84(1):82–83PubMedCrossRef
40.
go back to reference Gungor G, Ataseven H, Demir A, Solak Y, Gaipov A, Biyik M, et al. Neutrophil gelatinase-associated lipocalin in prediction of mortality in patients with hepatorenal syndrome: a prospective observational study. Liver Int. 2014;34(1):49–57PubMedCrossRef Gungor G, Ataseven H, Demir A, Solak Y, Gaipov A, Biyik M, et al. Neutrophil gelatinase-associated lipocalin in prediction of mortality in patients with hepatorenal syndrome: a prospective observational study. Liver Int. 2014;34(1):49–57PubMedCrossRef
41.
go back to reference Singer E, Marko L, Paragas N, Barasch J, Dragun D, Muller DN, et al. Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. Acta Physiol (Oxf). 2013;207(4):663–672CrossRef Singer E, Marko L, Paragas N, Barasch J, Dragun D, Muller DN, et al. Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. Acta Physiol (Oxf). 2013;207(4):663–672CrossRef
42.
go back to reference Barreto R, Elia C, Sola E, Moreira R, Ariza X, Rodriguez E, et al. Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. J Hepatol. 2014;61(1):35–42 Barreto R, Elia C, Sola E, Moreira R, Ariza X, Rodriguez E, et al. Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. J Hepatol. 2014;61(1):35–42
43.
go back to reference Fagundes C, Pepin MN, Guevara M, Barreto R, Casals G, Sola E, et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol. 2012;57(2):267–273PubMedCrossRef Fagundes C, Pepin MN, Guevara M, Barreto R, Casals G, Sola E, et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol. 2012;57(2):267–273PubMedCrossRef
44.
go back to reference Schrier RW. Fluid administration in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol. 2010;5(4):733–739PubMedCrossRef Schrier RW. Fluid administration in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol. 2010;5(4):733–739PubMedCrossRef
45.
go back to reference Ishikawa K, Wan L, Calzavacca P, Bellomo R, Bailey M, May CN. The effects of terlipressin on regional hemodynamics and kidney function in experimental hyperdynamic sepsis. PLoS ONE. 2012;7(2):e29693PubMedCentralPubMedCrossRef Ishikawa K, Wan L, Calzavacca P, Bellomo R, Bailey M, May CN. The effects of terlipressin on regional hemodynamics and kidney function in experimental hyperdynamic sepsis. PLoS ONE. 2012;7(2):e29693PubMedCentralPubMedCrossRef
46.
go back to reference Huang YY, Sun JY, Wang JY, Bai CX, He BM. Terlipressin resolves ascites of cirrhotic rats through downregulation of aquaporin 2. J Int Med Res. 2012;40(5):1735–1744PubMedCrossRef Huang YY, Sun JY, Wang JY, Bai CX, He BM. Terlipressin resolves ascites of cirrhotic rats through downregulation of aquaporin 2. J Int Med Res. 2012;40(5):1735–1744PubMedCrossRef
47.
go back to reference Esteva-Font C, Baccaro ME, Fernandez-Llama P, Sans L, Guevara M, Ars E, et al. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: relationship with ascites and hepatorenal syndrome. Hepatology. 2006;44(6):1555–1563PubMedCrossRef Esteva-Font C, Baccaro ME, Fernandez-Llama P, Sans L, Guevara M, Ars E, et al. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: relationship with ascites and hepatorenal syndrome. Hepatology. 2006;44(6):1555–1563PubMedCrossRef
48.
go back to reference Bellot P, Frances R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int. 2013;33(1):31–39PubMedCrossRef Bellot P, Frances R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int. 2013;33(1):31–39PubMedCrossRef
49.
go back to reference Bellot P, Garcia-Pagan JC, Frances R, Abraldes JG, Navasa M, Perez-Mateo M, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010;52(6):2044–2052PubMedCrossRef Bellot P, Garcia-Pagan JC, Frances R, Abraldes JG, Navasa M, Perez-Mateo M, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010;52(6):2044–2052PubMedCrossRef
50.
go back to reference Garcia-Tsao G, Albillos A, Barden GE, West AB. Bacterial translocation in acute and chronic portal hypertension. Hepatology. 1993;17(6):1081–1085PubMedCrossRef Garcia-Tsao G, Albillos A, Barden GE, West AB. Bacterial translocation in acute and chronic portal hypertension. Hepatology. 1993;17(6):1081–1085PubMedCrossRef
51.
go back to reference Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun. 1979;23(2):403–411PubMedCentralPubMed Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun. 1979;23(2):403–411PubMedCentralPubMed
52.
go back to reference Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53(6):1443–1454PubMedCrossRef Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53(6):1443–1454PubMedCrossRef
53.
go back to reference Gunnarsdottir SA, Sadik R, Shev S, Simren M, Sjovall H, Stotzer PO, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol. 2003;98(6):1362–1370PubMedCrossRef Gunnarsdottir SA, Sadik R, Shev S, Simren M, Sjovall H, Stotzer PO, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol. 2003;98(6):1362–1370PubMedCrossRef
54.
go back to reference Riordan SM, Williams R. The intestinal flora and bacterial infection in cirrhosis. J Hepatol. 2006;45(5):744–757PubMedCrossRef Riordan SM, Williams R. The intestinal flora and bacterial infection in cirrhosis. J Hepatol. 2006;45(5):744–757PubMedCrossRef
55.
go back to reference Such J, Guardiola JV, de JJ, Casellas JA, Pascual S, Aparicio JR, et al. Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2002; 14(4):371–376 Such J, Guardiola JV, de JJ, Casellas JA, Pascual S, Aparicio JR, et al. Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2002; 14(4):371–376
56.
go back to reference Misra V, Misra SP, Dwivedi M, Gupta SC. Histomorphometric study of portal hypertensive enteropathy. Am J Clin Pathol. 1997;108(6):652–657PubMed Misra V, Misra SP, Dwivedi M, Gupta SC. Histomorphometric study of portal hypertensive enteropathy. Am J Clin Pathol. 1997;108(6):652–657PubMed
57.
go back to reference Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992;103(1):264–274PubMed Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992;103(1):264–274PubMed
58.
go back to reference Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41(3):422–433PubMedCrossRef Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41(3):422–433PubMedCrossRef
59.
go back to reference Albillos A, Hera Ad AL, Reyes E, Monserrat J, Munoz L, Nieto M, et al. Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin. J Hepatol. 2004; 40(4):624–631 Albillos A, Hera Ad AL, Reyes E, Monserrat J, Munoz L, Nieto M, et al. Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin. J Hepatol. 2004; 40(4):624–631
60.
go back to reference Henriksen JH, Moller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol. 1998;29(2):328–341PubMedCrossRef Henriksen JH, Moller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol. 1998;29(2):328–341PubMedCrossRef
61.
go back to reference Acevedo J, Fernandez J, Prado V, Silva A, Castro M, Pavesi M, et al. Relative adrenal insufficiency in decompensated cirrhosis: relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology. 2013;58(5):1757–1765PubMedCrossRef Acevedo J, Fernandez J, Prado V, Silva A, Castro M, Pavesi M, et al. Relative adrenal insufficiency in decompensated cirrhosis: relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology. 2013;58(5):1757–1765PubMedCrossRef
62.
go back to reference Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut. 2005;54(5):718–725PubMedCentralPubMedCrossRef Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut. 2005;54(5):718–725PubMedCentralPubMedCrossRef
63.
go back to reference Moreau R, Hadengue A, Soupison T, Kirstetter P, Mamzer MF, Vanjak D, et al. Septic shock in patients with cirrhosis: hemodynamic and metabolic characteristics and intensive care unit outcome. Crit Care Med. 1992;20(6):746–750PubMedCrossRef Moreau R, Hadengue A, Soupison T, Kirstetter P, Mamzer MF, Vanjak D, et al. Septic shock in patients with cirrhosis: hemodynamic and metabolic characteristics and intensive care unit outcome. Crit Care Med. 1992;20(6):746–750PubMedCrossRef
64.
65.
go back to reference Tsai MH, Peng YS, Chen YC, Liu NJ, Ho YP, Fang JT, et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology. 2006;43(4):673–681PubMedCrossRef Tsai MH, Peng YS, Chen YC, Liu NJ, Ho YP, Fang JT, et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology. 2006;43(4):673–681PubMedCrossRef
66.
go back to reference Fede G, Spadaro L, Tomaselli T, Privitera G, Germani G, Tsochatzis E, et al. Adrenocortical dysfunction in liver disease: a systematic review. Hepatology. 2012;55(4):1282–1291PubMedCrossRef Fede G, Spadaro L, Tomaselli T, Privitera G, Germani G, Tsochatzis E, et al. Adrenocortical dysfunction in liver disease: a systematic review. Hepatology. 2012;55(4):1282–1291PubMedCrossRef
67.
go back to reference Bornstein SR. Predisposing factors for adrenal insufficiency. N Engl J Med. 2009;360(22):2328–2339PubMedCrossRef Bornstein SR. Predisposing factors for adrenal insufficiency. N Engl J Med. 2009;360(22):2328–2339PubMedCrossRef
68.
go back to reference Gaillard RC, Turnill D, Sappino P, Muller AF. Tumor necrosis factor alpha inhibits the hormonal response of the pituitary gland to hypothalamic releasing factors. Endocrinology. 1990;127(1):101–106PubMedCrossRef Gaillard RC, Turnill D, Sappino P, Muller AF. Tumor necrosis factor alpha inhibits the hormonal response of the pituitary gland to hypothalamic releasing factors. Endocrinology. 1990;127(1):101–106PubMedCrossRef
69.
go back to reference Theocharidou E, Krag A, Bendtsen F, Moller S, Burroughs AK. Cardiac dysfunction in cirrhosis—does adrenal function play a role? A hypothesis. Liver Int. 2012;32(9):1327–1332CrossRef Theocharidou E, Krag A, Bendtsen F, Moller S, Burroughs AK. Cardiac dysfunction in cirrhosis—does adrenal function play a role? A hypothesis. Liver Int. 2012;32(9):1327–1332CrossRef
70.
go back to reference Wong F, Nadim M, Kellum J, Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. 2011;60(5):702–709. doi:10.1136/gut.2010.236133 Wong F, Nadim M, Kellum J, Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. 2011;60(5):702–709. doi:10.​1136/​gut.​2010.​236133
Metadata
Title
Immunologic, hemodynamic, and adrenal incompetence in cirrhosis: impact on renal dysfunction
Authors
Louise Madeleine Risør
Flemming Bendtsen
Søren Møller
Publication date
01-01-2015
Publisher
Springer India
Published in
Hepatology International / Issue 1/2015
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-014-9581-1

Other articles of this Issue 1/2015

Hepatology International 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine